Use of off-label drugs in real clinical practice
Abstract
Sleep disorders, insomnia is a clinical syndrome characterized by sleep and daytime wakefulness disorders. The diagnosis is established on the basis of complaints, physical examination, history taking. Treatment of insomnia includes sleep hygiene, the appointment of drug therapy, psychotherapy. Many patients do not consider problems with sleep, especially of an episodic nature, a disease, and do not always complain of a sleep disorder to the doctor, and therefore do not receive adequate help. and engaged in self-treatment, which leads to adverse effects.
About the Authors
B. V. Agafonov
Moscow Regional Research Clinical Institute n.a. M. F. Vladimirsky
Russian Federation
Russian Federation
V. A. Kruglov
Moscow Regional Research Clinical Institute n.a. M. F. Vladimirsky
Russian Federation
Russian Federation
N. N. Shevtsova
Moscow Regional Research Clinical Institute n.a. M. F. Vladimirsky
Russian Federation
Russian Federation
References
1. Полуэктов М. Г., Бузунов Р. В., Авербух В. М., Вербицкий Е.В и др. Проект клинических рекомендаций по диагностике и лечению хронической инсомнии у взрослых // Consilium Medicum «Неврология и ревматология».-2016.- № 2. С. 41-51.
2. Полуэктов М. Г. Клинический алгоритм диагностического и лечебного выбора при инсомнии // Эффективная фармакотерапия. Неврология и Психиатрия. Спец. (12) / 2013. С. 20-22.
3. Левин Я. И., Елигулашвили Т. С., Посохов С. И. и др. Фармакотерапия инсомний: роль имована // Расстройства сна / под ред. Ю. А. Александровского, А. М. Вейна. СПб.: Медицинское информационное агенство, 1995. C. 56-61.
4. Schadeck B., Chelly M., Amsellem D. et al. Comparative efficacy of doxylamine and zolpidem for the treatment of common insomnia // Sep. Hop. Paris. 1996. Vol. 72. № 13-14. P. 428-439.
5. Левин Я. И. Клинический опыт применения зопиклона (Релаксон) при инсомнии // Эффективная фармакотерапия. Неврология и психиатрия. 2011. № 1. C. 14-20.
6. Левин Я. И., Стрыгин К. Н. Донормил в терапии инсомнии // Лечение нервных болезней. 2005. Т. 6. № 2 (16). С. 18-21.
7. Gracies J. M. Pathophysiology of spastic paresis. Emergence of muscle overactivity // Muscle and Nerve. 2005. Vol. 31. P. 552-578.
8. Hutchinson D. R. Modified release tizanidine: a review // J. Int. Med. Res. 1989. Vol. 17. P. 565-573.
9. Gelber D.A., Good D. C., Dromerick A. et al. Open-label dose-titration safety and efficacy study of Tizanidine hydrochloride in the treatment of spasticity associated with chronic stroke // Stroke. 2001.Vol. 32. P. 1841-1846.
10. Van Tulder MW, Touray T, Furlan AD, Solway S, Bouter LM; Cochrane Back Review Group. Muscle relaxants for nonspecific low back pain: a systematic review within the framework of the cochrane collaboration. Spine, 2003. Sep. 1, 28 (17): 1978-92.
Review
For citations:
Agafonov B.V., Kruglov V.A., Shevtsova N.N. Use of off-label drugs in real clinical practice. Medical alphabet. 2018;4(33):5-8. (In Russ.)
Views:
560
Email this article 